Funding profile · Digital health

Sepsis Scout

Seven years of accelerator cheques, a small federal grant and an undisclosed acquisition, with not one Form D on file at the SEC. The public totals for this company disagree by an order of magnitude.

$2.88MTotal raised, per PitchBook (aggregator estimate)
$254,320NIH SBIR Phase I, the only federal award on record
0Form D filings under either company name
16Investors listed by PitchBook, 5 of them named

Data as of September 23, 2026. Company-reported and aggregator figures are labeled.

Rounds at a glance

When Round Amount Investors Source
By 2017 muru-D accelerator, Sydney $40,000 muru-D (Telstra) Founder interview
Dec 1, 2017 Accelerator $75K Not named PitchBook
Mar 20, 2018 Accelerator, Y Combinator W18 $120K · $195K to date Y Combinator PitchBook, YC
Aug 7, 2018 Seed Not disclosed Not named PitchBook
2019 to 2022 Four further accelerator rounds, one undated Not disclosed Quinn names TMCx; MedTech Innovator appears in company materials PitchBook, interview
Sep 1, 2021 Early stage VC Not disclosed Not named PitchBook
Aug 2022 to Jul 2024 NIH SBIR Phase I $254,320 NIGMS NIH
Oct 20, 2023 Later stage VC, the final financing Not disclosed Not named PitchBook
Oct 23, 2024 Acquisition by Cytovale Terms not disclosed Cytovale Disclosure, PitchBook
Named investors Across all rounds Holdings not disclosed Y Combinator, muru-D, Kapor Capital, Gaingels, Allectus Capital, Colorful Capital, Constellar Ventures PitchBook, Tracxn

What the filings show

SEC EDGAR · no Form D on file · searched Sep 23, 2026

Registrant search
No EDGAR registrant named Patchd, Patchd Medical or Sepsis Scout
Full text search
Zero documents of any form type mentioning either name
Form D count
0, so no offering amount, investor count or related-person list exists
Related persons
Unknown from filings. Public records name only Robert Quinn (CEO, co-founder) and Wei-Jien Tan (CTO, co-founder and SBIR principal investigator)
Registered address
548 Market Street, Number 88172, San Francisco, CA 94104, per PitchBook

Reading the filings

  1. Silence at the SEC is not evidence of no money.An EDGAR registrant search and a full text search for both company names return nothing. Accelerator notes and SAFEs sold under Section 4(a)(2) require no Form D, which is the likely explanation for a company whose largest disclosed cheque was $120,000.
  2. The public totals are irreconcilable.PitchBook puts lifetime funding at $2.88M. Tracxn puts it at $210K across four rounds. Quinn said in a 2020 interview that the company had raised a couple of million. PitchBook shows amounts on only two of its nine financing rows, $75K and $120K, so about $2.68M of its own total is unattributed in the rows it displays.
  3. Non-dilutive money was a meaningful slice.The NIH SBIR Phase I of $254,320 is roughly 9 percent of PitchBook’s $2.88M total, and Quinn has also disclosed BARDA grant funding whose amount is not in the public award record. For a company of three to five people, that is a large share of the payroll.
  4. The exit landed thirteen days after the buyer got funded.Cytovale announced a $100 million Series D on Oct 10, 2024. PitchBook dates the Sepsis Scout acquisition Oct 23, 2024. The buyer had just closed the largest round in its history; the seller’s last financing was a year old.
  5. Only one equity holding in this company is documented in a primary source.It is not an investor’s. Professor Simon Finfer disclosed stock options in Sepsis Scout in JAMA, Lancet Respiratory Medicine and Intensive Care Medicine between 2024 and 2025. The company website quoted him endorsing the product without mentioning it.
  6. The company is gone as an independent entity.PitchBook marks the M&A row out of business, Quinn’s own 2025 journal disclosure says he is now employed by Cytovale, and the sepsisscout.com domain resolved in September 2026 to unrelated video content, not a company site.

Commercial signals

Signal Detail Source type
Regulatory No FDA clearance, approval or device listing under either name as of Sep 23, 2026. Not found
Clinical evidence No registered trial, no peer-reviewed validation of the algorithm. The 39 hour lead time claim is unpublished. Company-stated
Customers None named. A participant information site for a company study was live in April 2024. Company-stated
Intellectual property One US publication and one WO publication, both listed inactive by PitchBook. No granted US patent found. Public record
Acquirer Cytovale sells IntelliSep, an FDA cleared emergency department sepsis test (K220991, Dec 2022), and raised $100M in October 2024. Public record

What to watch

  • Any Cytovale disclosure that assigns value to the acquired wearable assets.
  • Assignment records on the patent family, which would show where the method ended up.
  • Publication of the NIH funded explainability work, which would be the first outside look at the algorithm.
  • Whether the named accelerator and venture backers ever mark a return on this position.

The Sepsis Scout story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Pair Team: Shared investor: Gaingels. A California medical group delivering Medicaid Enhanced Care Management to people living in shelters, cars and encampments
  • Osmind: Shared investor: Gaingels. An electronic health record for psychiatry practices delivering ketamine, esketamine and TMS, and a real world evidence business built on what those practices record
  • Arintra: Shared investor: Gaingels. Software that reads a finished patient chart and pushes billing codes straight into the claim, with no coder in between
  • Medplum: Shared investor: Gaingels. An open source, FHIR native electronic health record that developers install instead of licensing

Sources

  1. Public recordEDGAR registrant and full text searches for Patchd and Sepsis Scout, no resultsSEC · Sep 23, 2026
  2. Public recordNIH RePORTER 1R43GM148091-01NIGMS · FY2022
  3. Public recordPreventing, identifying, and managing sepsis in the community, author disclosuresLancet Primary Care · Jun 27, 2025
  4. Public recordAuthor disclosures citing stock options in Sepsis ScoutJAMA, Lancet Respiratory Medicine, Intensive Care Medicine · 2024 to 2025
  5. Public recordopenFDA 510(k) records: no match for Sepsis Scout or Patchd; Cytovale K220991FDA · Sep 23, 2026
  6. AggregatorSepsis Scout profile: deal history, investors, patents, acquisition datePitchBook · Sep 23, 2026
  7. AggregatorSepsis Scout profile: founders and investorsTracxn · Sep 23, 2026
  8. InterviewFrom UQ to Silicon Valley with Robert QuinnThe Router, UQ Computing Society · 2020
  9. CompanyCytovale Completes $100 Million Series D FundingPR Newswire · Oct 10, 2024
  10. CompanySepsis Scout website and study participant siteInternet Archive · 2022 to 2024

Compiled from SEC, NIH, FDA and other public records and published reports as of September 23, 2026. No Form D notice exists for this company; amounts shown from commercial databases are third-party estimates and are labeled as such. Healthcare Venture Capital Fund holds no position in Sepsis Scout or Cytovale. This page is not an offer to sell or a recommendation to buy any security.